Medicare Expands Coverage for GLP-1 Medications for Obesity
Medicare introduces coverage for GLP-1 medications targeting obesity, enhancing access for beneficiaries to affordable treatment options.
Novo Nordisk Seeks FDA Approval for Oral Anti-Obesity Drug Amid GLP-1 Market Competition
Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.